glp-1 monthly Search Behavior Is Evolving β Trends You Need To Know π¨ BIG NEWS FOR MEDICARE
Description
Today, we announced our investigational glucagon/GLP-1 dual receptor agonist achieved key measures of success at 48 weeks in our IMPACT Phase 2b trial and recent interactions with the FDA have resulted in alignment on the parameters for a registrational Phase 3 trial
Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.
It doesnt affect sugar glucose levels so you can enjoy high sweetness treats with overall less worries
Here's what you need to know:
How It Works
